Back to search
FDAFDA · Food and drugs·Recall number D-0018-2021

Losartan Potassium 100 mg, 30 Tabs bottles, Rx only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534 NDC 61919-952-30

Published October 14, 2020 · Recall initiated: April 30, 2019

Summary

FDA records drug Class II recall D-0018-2021, published October 14, 2020 and initiated April 30, 2019. Recalling firm: Direct Rx; Status: Terminated; Reported quantity: 33 bottles; Lot: Lot: 27AU1801 Exp. 02/28/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level per manufacturer

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Direct Rx
Distributor
GA
Lot
Lot: 27AU1801 Exp. 02/28/2021
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Losartan Potassium 100 mg, 30 Tabs bottles, Rx only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534 NDC 61919-952-30 recalled?

Yes. FDA published recall D-0018-2021 on October 14, 2020. Reported hazard: CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level per manufacturer

What should I do if I have this product?

Voluntary: Firm initiated · Letter